all report title image
  • Published On : Feb 2022
  • Code : CMI4917
  • Industry : Biotechnology
  • Pages : 154
  • Formats :

The measles and rubella (MR) vaccine, which protects against measles and rubella, is recommended by the Centers for Disease Control and Prevention (CDC). MR vaccine should be given to children in two doses, the first at 12 to 15 months of age and the second at 4 to 6 years of age. Measles is a highly contagious virus that continues to be one of the leading vaccine-preventable causes of childhood death. High fever and severe skin rash are among the symptoms of measles. Rubella is a virus-borne infectious disease. Rubella causes a mild sickness in most people, with symptoms such as a low-grade fever, sore throat, and a rash that begins on the face and spreads to the rest of the body. The majority of people who are vaccinated against measles and rubella (MR) will be protected for the rest of their lives. Vaccines and high immunization rates have made these diseases much less common in the U.S.

The MR vaccines market is estimated to be valued at US$ 5 million in 2021 and is expected to exhibit a CAGR of 2.1% over the forecast period (2021-2028).

Figure 1. MR Vaccines Market Share (%), By Region, 2021

MR Vaccines  | Coherent Market Insights

The increase in ongoing clinical trials is expected to drive growth of the MR vaccines market over the forecast period.

For instance, in November 2019, PT Bio Farma, an Indonesian state-owned enterprise, completed a Phase II / III clinical trial of Measles-Rubella (MR) vaccine. The study aimed to evaluate safety and immunogenicity of MR vaccine in Indonesian infants from 9 to 12 months of age.

CMI table icon

MR Vaccines Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 55.7 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 2.1% 2028 Value Projection: US$ 79.2 Mn
Geographies covered:
  • Commonwealth of Independent States (CIS) Countries: Russia, Uzbekistan, Kazakhstan, Ukraine, Turkmenistan, Belarus, and Armenia
  • Latin America: Brazil, Argentina, Mexico, Honduras, Colombia, Peru, and Chile
  • Europe: Turkey
  • Asia Pacific: Pakistan, Indonesia, Bangladesh, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Nepal, Sri Lanka, Papua New Guinea, and Mauritius
  • Middle East: Israel, UAE, Iraq, Iran, Saudi Arabia, Jordan, Qatar, Oman, and Syrian Arab Republic
  • Africa: South Africa, Nigeria, Tanzania, Democratic Republic of Congo, Ethiopia, Kenya, Egypt, Morocco, Ghana, Uganda, Burkina Faso, Angola, Algeria, Zimbabwe, Tunisia, Botswana, Libya, and Namibia
Segments covered:
  • By Vaccine Brand: MR Vaccine, MRBEV (BE LTD.)
  • By Distribution Channel: Public, Private
Companies covered:

PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG 

Growth Drivers:
  • The increasing cases of measles and rubella (MR)
  • Increasing research and development activities and ongoing clinical trials for the development of safe MR vaccines
  • Rising government initiatives to launch vaccine campaigns
Restraints & Challenges:
  • Risk of adverse reactions associated with measles and rubella (MR) vaccines

Figure 2. MR Vaccines Market Share (%), By Distribution Channel, 2021

MR Vaccines  | Coherent Market Insights

The increasing government initiatives to launch vaccine campaigns is expected to drive the market growth over the forecast period.

For instance, in January 2020, the Ministry of Health and Family Welfare (MOHFW) launched Measles and Rubella vaccination campaign with support from UNICEF and World Health Organization (WHO). An objective of this campaign was to reach all children with age group 6 months to children less than 10 years at the Rohingya refugee camps of stateless Indo-Aryan people.

MR Vaccines Market– Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. While the COVID-19 measures such as social distancing, masks, and hand hygiene also minimized the spread of the measles virus.

For instance, according to the data published by World Health Organization (WHO), in November 2021, more than 22 million infants missed their first dose of measles vaccine throughout 2020 and more than 3 million in 2019. This resulted in a hike in measles incidence. In addition, 24 measles vaccination campaigns planned for 2020 in 23 countries, were postponed due to COVID-19 pandemic which left more than 93 million people at risk for the disease. Such campaigns are required for people who have missed out on measles-rubella vaccines. The COVID-19 pandemic made significant disruptions to immunization services and changes in health-seeking nature in many parts across the globe.

MR Vaccines Market Restraint

The risk of adverse reactions associated with measles and rubella (MR) vaccines are expected to hinder the growth of the MR vaccines market over the forecast period.

For instance, according to a report published by the U.S. National Library of Medicine in January 2021, adverse reactions related to Measles and Rubella vaccination are fever, followed by vomiting, abdominal pain, and dizziness. After 4-5 days of MR vaccine administration, few children may have abnormal body movements. In few cases, altered sensorium was detected on the same day as vaccine delivery.

Key Players

Major players operating in the MR vaccines market include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG.

Measles and rubella is a live virus vaccine that protects against infection with the measles and rubella viruses. It works by causing the body to produce its antiviral defenses (antibodies). Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is a highly contagious infectious disease. Measles infection can result in significant complications such as pneumonia, ear infections, sinus infections, convulsions (seizures), brain damage, and death. Adults and children under the age of 5 years are at a higher risk of serious complications and mortality. When pregnant women contract rubella (also known as German measles), it can result in miscarriages, stillbirths, or birth abnormalities in their unborn children.

Market Dynamics

Measles and Rubella (MR) vaccine is a subcutaneous injection for active immunization against Measles and Rubella in young adults, adolescents, children, and infants at risk. Increasing incidence of Measles and Rubella (MR), ongoing clinical trials to develop MR vaccines, growing awareness about immunization services, rising government initiatives to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are the major factors that are expected to drive growth of the MR vaccines market over the forecast period.

For instance, according to the World Health Organization (WHO), from January 2020 to April 2021, eight African nations experienced major measles outbreaks that affected tens of thousands of children, owing to delayed vaccination programs or low routine immunization coverage.

Key features of the study:

  • This report provides an in-depth analysis of the MR vaccines market, and provides market size (US$ Mn. and No. of Doses in Mn.), and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the MR vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The MR vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MR vaccines market

Detailed Segmentation:

  • MR Vaccines Market, By Vaccine Brand:
    • MR Vaccine
    • MRBEV (BE LTD.)
  • MR Vaccines Market, By Distribution Channel:
    • Public
    • Private
  • MR Vaccines Market, By Region:
    • Commonwealth of Independent States (CIS) Countries
      • By Country
        • Russia
        • Uzbekistan
        • Kazakhstan
        • Ukraine
        • Turkmenistan
        • Belarus
        • Armenia
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Honduras
        • Colombia
        • Peru
        • Chile
    •  Europe
      • By Country
        • Turkey
    • Asia Pacific
      • By Country
        • Pakistan
        • Indonesia
        • Bangladesh
        • Philippines
        • Vietnam
        • Thailand
        • Myanmar
        • Malaysia
        • Cambodia
        • Nepal
        • Sri Lanka
        • Papua New Guinea
        • Mauritius
    • Middle East
      • By Country
        • UAE
        • Israel
        • Iraq
        • Iran
        • Saudi Arabia
        • Jordan
        • Qatar
        • Oman
        • Syrian Arab Republic
    • Africa
      • By Country/Region
        • Nigeria
        • Tanzania
        • Democratic Republic of Congo
        • Ethiopia
        • Kenya
        • South Africa
        • Egypt
        • Morocco
        • Ghana
        • Uganda
        • Burkina Faso
        • Angola
        • Algeria
        • Zimbabwe
        • Tunisia
        • Botswana
        • Libya
        • Namibia
  • Company Profiles
    • PT Bio Farma*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bio-Manguinhos
    • BE Vaccines
    • Serum Institute of India
    • Crucell Switzerland AG

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The MR vaccines market size is estimated to be valued at US$ 55.7 million in 2021 and is expected to exhibit a CAGR of 2.1% between 2021 and 2028.
The increasing cases measles and rubella (MR), increasing research and development activities and ongoing clinical trials for the development of safe MR vaccines, rising government initiative to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are expected to drive the market growth over the forecast period.
MR vaccine segment is expected to hold a major market share in the market.
Asia Pacific holds the largest market share in the market. 
Major factors hampering growth of the market include risk of adverse reactions associated with measles and rubella (MR) vaccines.
Major players operating in the market include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo